Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q1 FY27ended Jun 30, 2026 | Aug 10, 2026 | −$0.26 | — | $1.44M | −33.5% | −$0.33 |
| Q4 FY26ended Mar 31, 2026 | Jun 4, 2026 | $0.42 | — | $2.52M | −66.7% | −$0.26 |
| Q3 FY26ended Dec 31, 2025 | — | −$0.38 | −265.2% | $2.00M | −77.8% | — |
| Q2 FY26ended Sep 30, 2025 | — | −$0.17 | — | $1.57M | −64.9% | — |
| Q1 FY26ended Jun 30, 2025 | — | −$0.33 | −375.0% | $2.17M | −72.8% | — |
| Q4 FY25ended Mar 31, 2025 | — | −$0.31 | — | $7.57M | −16.1% | — |
| Q3 FY25ended Dec 31, 2024 | — | $0.23 | −96.2% | $9.02M | −42.1% | — |
| Q2 FY25ended Sep 30, 2024 | — | −$0.31 | — | $4.48M | +22.7% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Roivant Sciences shares, not any token. As of Aug 10, 2026, from Massive's standardised financials and the earnings calendar.
| Q1 FY25ended Jun 30, 2024 | — | $0.12 | — | $7.99M | — | — |
| Q4 FY24ended Mar 31, 2024 | — | −$0.16 | — | $9.02M | — | — |
| Q3 FY24ended Dec 31, 2023 | — | $6.03 | — | $15.56M | — | — |
| Q2 FY24ended Sep 30, 2023 | — | −$0.40 | — | $3.65M | — | — |